| pubmed-article:7812800 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7812800 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:7812800 | lifeskim:mentions | umls-concept:C0008407 | lld:lifeskim |
| pubmed-article:7812800 | lifeskim:mentions | umls-concept:C0030616 | lld:lifeskim |
| pubmed-article:7812800 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
| pubmed-article:7812800 | lifeskim:mentions | umls-concept:C0101767 | lld:lifeskim |
| pubmed-article:7812800 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7812800 | pubmed:dateCreated | 1995-2-3 | lld:pubmed |
| pubmed-article:7812800 | pubmed:abstractText | Rats received bilateral intracerebroventricular (ICV) infusions of either AF64A (1.5 nmol/ventricle; n = 9) or vehicle (3.0 microliters/ventricle; n = 7). Four weeks later, the animals were anesthetized and their brains processed to visualize and quantify choline acetyltransferase (ChAT) immunoreactive (IR) and parvalbumin-IR GABAergic neurons in the septal complex by immunocytochemistry (PAP method). AF64A significantly reduced the number of ChAT-IR perikarya in the medial septum (28%), ventral limb of the diagonal band of Broca (30%), and horizontal limb of the diagonal band of Broca (20%), but did not affect the number of parvalbumin-containing GABAergic neurons in any of the septal subdivisions. These results provide further evidence that AF64A is a selective cholinotoxin. | lld:pubmed |
| pubmed-article:7812800 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7812800 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7812800 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7812800 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7812800 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7812800 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7812800 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7812800 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7812800 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7812800 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7812800 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7812800 | pubmed:issn | 0361-9230 | lld:pubmed |
| pubmed-article:7812800 | pubmed:author | pubmed-author:HaninII | lld:pubmed |
| pubmed-article:7812800 | pubmed:author | pubmed-author:LorensS ASA | lld:pubmed |
| pubmed-article:7812800 | pubmed:author | pubmed-author:DongX WXW | lld:pubmed |
| pubmed-article:7812800 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7812800 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:7812800 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7812800 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7812800 | pubmed:pagination | 217-20 | lld:pubmed |
| pubmed-article:7812800 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:meshHeading | pubmed-meshheading:7812800-... | lld:pubmed |
| pubmed-article:7812800 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7812800 | pubmed:articleTitle | AF64A affects septal choline acetyltransferase but not parvalbumin immunoreactive cells. | lld:pubmed |
| pubmed-article:7812800 | pubmed:affiliation | Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153. | lld:pubmed |
| pubmed-article:7812800 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7812800 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7812800 | lld:pubmed |
